Drug intelligence / Profile preview

CBK-323

Development stage: Preclinical
Lead developer: Scripps Research
Modality: Small Molecules

Overview

CBK-323 is a small molecule drug initially developed by The Scripps Research Institute. It is being investigated for the treatment of respiratory diseases, with primary indications including chronic obstructive pulmonary disease (COPD) and adult respiratory distress syndrome. As of March 2025, its highest development status is preclinical. Detailed information on its mechanism of action or molecular targets has not been disclosed in public sources[1][2].

Beyond the preview

Go deeper on CBK-323.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBK-323.

Explore the full profile